Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Inc is an American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. The enterprise focuses on developing RNAi-based drugs targeting rare genetic, cardio-metabolic, and infectious diseases. Revenue is primarily generated from commercial product sales of proprietary medicines including Onpattro, Givlaari, Oxlumo, and Amvuttra, alongside strategic partnership royalties. Alnylam occupies a pioneering global leadership position as the premier commercial provider of RNAi therapeutics. Its primary end markets include academic medical centers, rare disease specialists, and patients affected by genetic disorders worldwide. The company is headquartered in Cambridge, Massachusetts, and its common stock is traded on the Nasdaq Stock Market.
46 of the funds FundTelligence covers report a position in Alnylam Pharmaceuticals.
- Legal name
- Alnylam Pharmaceuticals Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 46
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Alnylam Pharmaceuticals
- DNB Bioteknologi — DNB · 2.95 % (full portfolio disclosed, September 2026)
- Baillie Gifford Worldwide Positive Change Fund — Baillie Gifford · 2.4 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.34 % (full portfolio disclosed, October 2026)
- FTGF ClearBridge US Value Fund — Franklin Templeton · 1.25 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.05 % (full portfolio disclosed, September 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.86 % (full portfolio disclosed, December 2025)
- JPM Global Healthcare Fund — JPM · 0.77 % (full portfolio disclosed, June 2026)
- Baillie Gifford Worldwide Responsible Global Alpha Paris-Aligned Fund — Baillie Gifford · 0.53 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 46 funds holding it.